Cash, cash equivalents and investments were $541.3 million as of December 31, 2022, which is anticipated to fund operations into fiscal 2026.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PNT:
- POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
- POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Point Biopharma: SPLASH trial not experiencing manufacturing, drug supply issues
- POINT Biopharma to Participate in Upcoming Investor Conferences